HOW DOES CYCLIN D1 BEHAVIOR AS A BIOMARKER IN PAPILLIFEROUS THYROID CARCINOMAS AND MULTINODULAR GOITERS?

• Autor(a) principal: Bartolomei , Ivan José Paredes
• Data de Publicação: 2023
• Outros Autores: Ribas, Carmen Austrália Paredes Marcondes, Zella , Maria Augusta Karas, Waaga-Gasser, Ana Maria, Gasser, Martin, Czeczko , Nicolau Gregori, Nassif , Paulo Afonso Nunes, Manso , Jose Eduardo Ferreira, Torres , Orlando Jorge Martins
• Tipo de documento: preprint
• Idioma: por
• Título da fonte: SciELO Preprints
• Texto Completo: https://preprints.scielo.org/index.php/scielo/preprint/view/7751
• topic: Carcinomas papilíferos de tireoide; Ciclina D1; Imunoistoquímica; Diagnóstico; Prognóstico; Papillary thyroid carcinomas; Cyclin D1; Immunohistochemistry; Diagnosis; Prognosis

Introduction: Papillary carcinomas are the most prevalent and least aggressive thyroid carcinomas (PTC). In some cases, the diagnosis is doubtfull and the prognosis is poor. The search for tissue biomarkers that ensure both the diagnosis for indeterminate cases and the prognosis, identifying the most aggressive cases, has been studied in recent decades. Objective: To review the literature in search of cyclin D1 as a marker of papillary thyroid carcinomas and multinodular goiters and evaluate whether its expression correlates with the clinicopathological characteristics of papillary thyroid carcinomas. Methods: Narrative review carried out by collecting information for reading and analysis from online research on virtual platforms. Initially, a search was carried out from MESH descriptors related to the topic, using the following terms: “papillary thyroid carcinoma, cyclin D1, immunohistochemistry, diagnosis, prognosis.” with AND or OR search, considering the title and/or abstract and those chosen were read in full. Results: The search included 77 articles that were compiled in this review. Conclusion: Cyclin D1 was expressed in the vast majority of PTCs, with diffuse distribution being predominant. There was no correlation between its expression and any clinicopathological characteristic of PTC.